Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China

Sun, Lijun; Shen, Lijun; Fan, Junfen; Gu, Fei; Hu, Mei; An, Yiran; Zhou, Qing; Fan, Hao; Bi, Jian

doi:10.1002/jmv.25966

Cited by 76 publications

(52 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of 1,099 hospitalised patients, Guan et al reported the presence of fever in 44% of the cases at hospital admission (20). A total of 93% of the patients had a cough in our study; in other studies, the incidence of cough varied from 48.7% to 65.5% (15,17,19,21). Dyspnoea was present in 85% of the patients with severe pneumonia, in contrast with the meta-analysis and systematic review of Zhao et al, which reported dyspnoea in 44.2% of patients with severe pneumonia (95% CI: 7.8-80.6) and in 5.7% of patients with non-severe infection (95% CI: 0-10.7%) (22); moreover, dyspnoea has been reported as a marker of severe and progressive disease (23)(24)(25).…”

Section: Discussionsupporting

confidence: 43%

Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia

Yomayusa¹,

Acevedo²,

Reina³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Coronavirus disease (COVID-19) represents an unprecedented challenge for both people and health systems. Latin America is the current epicentre of the pandemic; however, there is little published clinical information on the clinical characteristics and outcomes.Objective: To analyse the clinic characteristics, risk factors and evolution of the first cohort of hospitalised patients with confirmed infection by COVID-19 in 5 Colombian institutions.Methods: In the present retrospective observational study, information was acquired from consecutive hospitalized patients with a diagnosis of COVID-19 confirmed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) from March 01 to May 30, 2020 in Colombia.Results: A total of 44 patients were included. The median age was 62 years, and 65.9% of the patients were male. A total of 69.8% of the patients were overweight or obese, and 13.6% of the patients had high blood pressure and diabetes. The presence of systemic symptoms and cough were the most common. Ground-glass opacity was frequent finding upon chest imaging. The 30-day mortality rate was 47.7% with a median of 11 days. The composite outcome (critical care requirement, mechanical ventilation and death) occurred in 36.4% of the patients. The biomarkers associated with mortality risk included troponin higher than 14 ng/L (RR: 5.25; 95% CI 1.37-20.1, p = 0.004) and D-dimer higher than 1000 ng/ml (RR: 3.0; 95% CI 1.4-6.3, p = 0.008). Cardiovascular complications, acute respiratory distress syndrome (ARDS) and acute kidney injury were the most frequent comorbidities in patients with severe pneumonia.Conclusion: The clinical course of SARS-CoV-2 infection diagnosis confirmed by RT-PCR in Colombian patients admitted to a high-complexity hospital was similar to that reported in the literature; however, the population was characterised by a more advanced stage of the infection.

show abstract

Section: Discussionsupporting

confidence: 43%

Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia

Yomayusa¹,

Acevedo²,

Reina³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Lu et al reported that COVID‐19 patients with high levels of ferritin have greater proportions of severe and deceased cases ( P = .0016) 30 . Similarly, Sun et al revealed that severe patients and discharged patients have greater proportions of increased level of ferritin than non‐severe patients and hospitalized patients (100% vs. 50%, 92.3% vs. 37.9% respectively, P < .001) and suggested that serum ferritin is a potential risk factor of poor prognosis in COVID‐19 patients 68 . In the study by Hou et al, ferritin was selected as a prediction marker of severe COVID‐19 by multivariable logistic regression analysis [odds ratio (OR) = 1.0006 (97.5% CI 1.0001‐1.0010), P = .206] and the area under the curve (AUC) to differentiate critical from mild patients was 0.812 69 …”

Section: Resultsmentioning

confidence: 93%

Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis

Cheng

et al. 2020

Clinical Laboratory Analysis

319

251

View full text Add to dashboard Cite

Objective The coronavirus disease 2019 (COVID‐19) has rapidly developed into a pandemic. Increased levels of ferritin due to cytokine storm and secondary hemophagocytic lymphohistiocytosis were found in severe COVID‐19 patients. Therefore, the aim of this study was to determine the role of ferritin in COVID‐19. Methods Studies investigating ferritin in COVID‐19 were collected from PubMed, EMBASE, CNKI, SinoMed, and WANFANG. A meta‐analysis was performed to compare the ferritin level between different patient groups: non‐survivors versus survivors; more severe versus less severe; with comorbidity versus without comorbidity; ICU versus non‐ICU; with mechanical ventilation versus without mechanical ventilation. Results A total of 52 records involving 10 614 COVID‐19‐confirmed patients between December 25, 2019, and June 1, 2020, were included in this meta‐analysis, and 18 studies were included in the qualitative synthesis. The ferritin level was significantly increased in severe patients compared with the level in non‐severe patients [WMD 397.77 (95% CI 306.51‐489.02), P < .001]. Non‐survivors had a significantly higher ferritin level compared with the one in survivors [WMD 677.17 (95% CI 391.01‐963.33), P < .001]. Patients with one or more comorbidities including diabetes, thrombotic complication, and cancer had significantly higher levels of ferritin than those without (P < .01). Severe acute liver injury was significantly associated with high levels of ferritin, and its level was associated with intensive supportive care, including ICU transfer and mechanical ventilation. Conclusions Ferritin was associated with poor prognosis and could predict the worsening of COVID‐19 patients.

show abstract

“…Studies show that severe disease seems to be determined by socio-demographic characteristics including male sex and older age. Having a history of pre-existing co-morbid illness particularly hypertension, diabetes, severe asthma, cancer, renal disease, cardiovascular, cerebrovascular diseases, and other co-morbidities were also found to be predictors of severe disease [2][3][4][5][6][7][8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Disease Severity and Associated Factors among Ethiopian Patients: A study of the Millennium COVID-19 Care Center

Leulseged

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Understanding determinants of developing severe COVID-19 disease is important as studies show that severe disease is associated with worse outcomes. Objective: The study aimed to assess the determinants of COVID-19 disease severity among COVID-19 patients admitted to Millennium COVID-19 Care Center in Ethiopia. Methods: A cross-sectional study was conducted from June to August 2020 among randomly selected 686 patients. Chi-square test was used to detect the presence of a statistically significant difference in the characteristics of the patients based on disease severity (Mild Vs Moderate Vs Severe), where p-value of <0.05 was considered as having a statistically significant difference. A Multivariable multinomial logistic regression model was used to assess the presence of a significant association between the independent variables and COVID-19 disease severity where Adjusted Odds ratio (AOR), 95% CIs for AOR and P-values were used for testing significance and interpretation of results. Results: Having moderate as compared with mild disease was significantly associated with having hypertension (AOR= 2.302, 95% CI= 1.266, 4.184, p-value=0.006), diabetes mellitus (AOR=2.607, 95% CI= 1.307, 5.198, p-value=0.007 for diabetes mellitus), fever (AOR= 6.115, 95% CI= 2.941, 12.716, p-value=0.0001) and headache (AOR= 2.695, 95% CI= 1.392, 5.215, p-value=0.003). Similarly, having severe disease as compared with mild disease was associated with age group (AOR= 4.428, 95% CI= 2.497, 7.853, p-value=0.0001 for 40-59 years and AOR=18.070, 95% CI=9.292, 35.140, p-value=0.0001 for ≥ 60 years), sex (AOR=1.842, 95% CI=1.121, 3.027, p-value=0.016), hypertension (AOR= 1.966, 95% CI= 1.076, 3.593, p-value=0.028), diabetes mellitus (AOR= 3.926, 95% CI= 1.964, 7.847, p-value=0.0001), fever (AOR= 13.218, 95% CI= 6.109, 28.601, p-value=0.0001) and headache (AOR= 4.816, 95% CI= 2.324, 9.979, p-value=0.0001). In addition, determinants of severe disease as compared with moderate disease were found to be age group (AOR= 4.871, 95% CI= 2.854, 8.315, p-value=0.0001 for 40-59 years and AOR= 18.906, 95% CI= 9.838, 36.334, p-value=0.0001 for ≥ 60 years), fever (AOR= 2.161, 95% CI= 1.286, 3.634, p-value=0.004) and headache (AOR= 1.787, 95% CI= 1.028, 3.107, p-value=0.039). Conclusions: Being old, male sex, hypertension, diabetes mellitus, and having symptoms of fever and headache were found to be determinants of developing a more severe COVID-19 disease category. We recommend a better preventive practice to be set in place so that these groups of patients can be protected from acquiring the disease. And for those who are already infected, a more careful follow-up and management should be given so that complication and death can be prevented. Furthermore, considering the above non respiratory symptoms as disease severity indicator could be important.

show abstract

Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China

Cited by 76 publications

References 35 publications

Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia

Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia

Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis

COVID-19 Disease Severity and Associated Factors among Ethiopian Patients: A study of the Millennium COVID-19 Care Center

Contact Info

Product

Resources

About